CorVel (CRVL) has drawn investor interest after recent share price moves, with the stock down about 4% on the day but higher over the past week, month, and past 3 months.

Zooming out, CorVel’s recent pullback comes after a period of strong short term share price momentum, with a 24.6% 90 day share price return contrasting with a 46.3% decline in 1 year total shareholder return. This indicates that sentiment has been shifting quickly.

If you are rethinking your watchlist after CorVel’s sharp swings, it could be worth widening the search and checking a screener of 33 healthcare AI stocks

So with CorVel trading at an intrinsic value estimate suggesting about a 5% discount and a recent mix of sharp gains and longer term weakness, is this a genuine opening or is the market already pricing in future growth?

Price to Earnings of 28.5x: Is it justified?

On a P/E of 28.5x, CorVel trades at a higher earnings multiple than the broader US Healthcare sector, even though the share price is currently about 5% below an intrinsic value estimate.

The P/E ratio links the current share price to the company’s earnings, so a higher multiple usually reflects strong profitability, expectations for continued earnings growth, or both. CorVel reports high quality earnings and a Return on Equity of 28%, which is above the 20% level often viewed as strong, and earnings have grown by 14.5% per year over the past 5 years, with 16% growth in the most recent year.

Compared with the US Healthcare industry average P/E of 24.5x, CorVel’s 28.5x multiple is more expensive, so the market is putting a premium on its earnings relative to sector peers. Against a peer group average P/E of 85.6x, however, the stock trades at a lower multiple, which shows a large gap between how the broader peer set is priced and CorVel’s current valuation.

Result: Price-to-Earnings of 28.5x (ABOUT RIGHT)

However, the story could shift quickly if pricing for its workers’ compensation and liability services tightens, or if AI driven cost savings fall short of expectations.

Another View: Cash Flows Point to Mild Undervaluation

While the 28.5x P/E suggests CorVel is roughly in line with its earnings power, the SWS DCF model approaches the question from a different angle and values the stock at about $65.03 per share, compared with the current price of $61.54. That roughly 5% gap hints at a modest cushion rather than a steep bargain, so the key question is whether you place more weight on the earnings multiple or on the cash flow calculations.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CorVel for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The mix of recent share price swings, solid profitability metrics, and a small DCF gap leaves the story finely balanced. It is worth reviewing the numbers yourself and deciding how comfortable you are with both the potential upside and the risks on the table. To help weigh those trade offs, take a closer look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If CorVel is on your radar, it makes sense to line it up against other clear opportunities so you are not leaving potential ideas unexplored.

• Target stability first by scanning companies with resilient finances using the solid balance sheet and fundamentals stocks screener (46 results).
• Spot potential value candidates quickly by reviewing the 53 high quality undervalued stocks before prices move away from you.
• Hunt for future standouts early by checking the screener containing 20 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.